Scientific Advisory Board
Dr Daniel Bracewell, EngD
Daniel G. Bracewell is a Reader in Bioprocess Analysis at the UCL Department of Biochemical Engineering. He has made major contributions to the fundamental understanding of biopharmaceutical purification operations, generating over £5.5 million in research funds including new international research collaborations with India and the USA. He has authored more than 70 peer reviewed journal articles in the area to date and currently supervises 15 doctoral and postdoctoral projects, many of these studies are in collaboration with industry. A previous research project is the basis for the technology from which Puridify has developed.
Prof Barry Buckland, PhD
Barry has obtained a PhD in Biochemical Engineering at University College London in 1974. He joined the Merck Research Laboratories (MRL) in 1980 and built a world class Bioprocess R&D group leading process development of all biologically made product candidates within the MRL pipeline and the manufacture of Clinical Supplies during a 20 year time frame. Products developed within this period include MEVACOR®, ZOCOR®, IVOMEC®, CANCIDAS®, RECOMBIVAX HB®, VAQTA®, VARIVAX®, COMVAX®., ROTATEQ® (Rotavirus vaccine), ZOSTAVAX® (shingles vaccine) and GARDASIL® (HPV vaccine).
Dr Karol Łącki, PhD
Karol Łącki received his Bachelor and later Master in Applied Science degree in Process and Chemical Engineering from the Warsaw Technical University, Poland, and his Ph.D. degree in Chemical Engineering from the University of Ottawa, Canada. In his previous roles Karol has lead the Mathematical Modelling department at Novo Nordisk, Denmark. Before that, he had spent 17 years working for GE Healthcare R&D in Uppsala, Sweden, conducting research pertaining to development of chromatography resin, modeling and optimization of separation processes.
Dr Will Lewis, EngD
Will gained an EngD in Bioprocessing looking at the manufacture of camelid antibody fragments at University College London sponsored by Unilever. In 2008 he then moved to GSK in Stevenage developing processes to purify domain antibodies in preparation for clinical manufacture, then expanding into other formats including mAbs, novel mAb-like proteins and recombinant proteins. He now leads the downstream process research group which specialises in de-risking the downstream processing of new biopharm molecules and accelerating them into early clinical manufacture in conjunction with wider functions in cell line development, upstream, analytical and formulation.
Dr John Liddell, PhD
John most recently held senior bioprocessing development positions with Fujifilm Diosynth Biotechnologies developing and applying innovative solutions for a diverse range of biotherapeutic proteins for the company’s international client base. Prior to Fujifilm he held senior bioprocessing development roles in ICI, Zeneca, Avecia and Merck. He has almost 30 years’ experience in bioprocess development with broadly based experience covering recovery of biopharmaceutical products from both microbial and mammalian cell expression systems. Bioprocessing experience has covered a very diverse range of biopharmaceutical proteins and other molecules as well as earlier IBB experience.